awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
1078-0432.CCR-13-3445
1078-0432.CCR-13-3445
http://dx.doi.org/10.1158/1078-0432.CCR-13-3445
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
P356
Q27853079-9218290F-E719-4DDB-850F-BAFE55616E46
P356
1078-0432.CCR-13-3445
http://dx.doi.org/10.1158/1078-0432.CCR-13-3445